Bicara Therapeutics Inc. (BCAX) Key Metrics
BCAX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.11B
- Enterprise value
- $859.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 2.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.69
BCAX key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBCAX valuation Price multiples at each fiscal year-end price.
BCAX returns How much profit the business earns on the capital it uses.
BCAX per-share figures Results divided by the shares outstanding at year-end.
BCAX financial health Debt, liquidity and how easily interest is covered.
BCAX valuation history
BCAX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BCAX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BCAX price vs earnings per share
BCAX key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $920.2M | $948.1M | — | — |
| Enterprise value | $507.1M | $459.1M | — | — |
| Price / book | 2.3 | 1.9 | — | — |
| Earnings yield | −15.0% | −7.2% | — | — |
| Free cash flow yield | −11.6% | −7.9% | — | — |
| Share price at fiscal year-end | $16.83 | $17.42 | — | — |
| Per share | ||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$2.52 | −$1.25 | −$1.00 | −$0.73 |
| Operating cash flow per share | −$1.95 | −$1.37 | −$0.88 | −$0.62 |
| Free cash flow per share | −$1.96 | −$1.37 | −$0.89 | −$0.62 |
| Cash per share | $7.59 | $9.00 | $4.45 | $0.08 |
| Book value per share | $7.34 | $9.04 | $4.22 | −$0.33 |
| Tangible book value per share | $7.34 | $9.04 | $4.22 | −$0.33 |
| Capex per share | $0.01 | $0.00 | $0.01 | $0.00 |
| Debt per share | $0.03 | $0.01 | $0.01 | — |
| Shares outstanding | 54.7M | 54.4M | 51.8M | 51.8M |
| Change in shares outstanding | +0.5% | +5.1% | 0.0% | — |
| Returns & profitability | ||||
| Return on equity (ROE) | −30.9% | −19.1% | −51.7% | — |
| Return on assets (ROA) | −27.6% | −16.9% | −43.2% | −564.6% |
| Return on tangible assets | −32.0% | −11.9% | −22.2% | −564.6% |
| Financial health | ||||
| Total debt | $1.7M | $738,000 | $657,000 | — |
| Cash & short-term investments | $414.8M | $489.7M | $230.4M | $4.2M |
| Net debt | −$413.1M | −$489.0M | −$229.8M | −$4.2M |
| Debt / equity | 0.00 | 0.00 | 0.00 | — |
| Debt / assets | 0.00 | 0.00 | 0.00 | — |
| Current ratio | 14.58 | 27.93 | 15.32 | 0.21 |
| Quick ratio | 14.58 | 27.93 | 15.32 | 0.21 |
| Interest coverage | — | — | — | -336.2 |
| Working capital | $393.1M | $484.5M | $216.0M | −$18.9M |
| Invested capital | −$11.6M | $2.9M | −$11.3M | −$21.4M |
| Tangible asset value | $401.5M | $491.9M | $218.5M | −$17.3M |
| Net current asset value | $392.5M | $425.2M | $215.6M | −$19.0M |
| Graham net-net per share | $7.05 | $7.58 | $4.15 | −$0.38 |
| Capital allocation | ||||
| Capex / depreciation | 2.67 | 1.27 | 30.84 | 19.20 |
| Efficiency | ||||
| Days payables outstanding | — | 25,074.2 | 79,944.6 | 187,500.5 |
| Payables turnover | — | 0.01 | 0.00 | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $6.2M | $3.8M | $4.2M | $5.1M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from BCAX's annual financial statements (latest annual report filed March 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BCAX valuation and financial ratios
Bicara Therapeutics earned a return on equity of −30.9% in fiscal 2025. It ended the year with $1.7 million of debt and $414.8 million in cash and short-term investments, a net cash position of $413.1 million.
See the BCAX income statement, the BCAX chart for price history, or the BCAX stock overview for the latest quote and news.
BCAX key metrics FAQ
What is Bicara Therapeutics's return on equity?
Bicara Therapeutics's return on equity (ROE) was −30.9% in fiscal 2025: net income of -$137.9 million on average shareholders' equity of $446.7 million.
How much debt does Bicara Therapeutics have?
Bicara Therapeutics had total debt of $1.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Bicara Therapeutics's free cash flow yield?
Bicara Therapeutics generated -$107.1 million of free cash flow in fiscal 2025, a free cash flow yield of −11.6% on its market value at year-end ($920.2 million).
What is Bicara Therapeutics's current ratio?
Bicara Therapeutics's current ratio was 14.58 at the end of fiscal 2025: current assets were 14.58 times current liabilities.